Virtu Financial LLC Monopar Therapeutics Transaction History

Virtu Financial LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$0.59 - $0.94 $2,942 - $4,687	-4,987 Reduced 20.93%	18,840 $14,000
Q1 2024 May 20, 2024	SELL	$0.31 - $1.35 $1,036 - $4,513	-3,343 Reduced 12.3%	23,827 $16,000
Q4 2023 Feb 26, 2024	BUY	$0.29 - $0.6 $7,879 - $16,302	27,170 New	27,170 $9,000

Ticker MNPR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,725,800
Market Cap $316M
Description
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe ...

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.